Business Context and Reporting Period
Company: Revolution Medicines, Inc. (RVMD)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: Revolution Medicines is a clinical-stage precision oncology company developing novel targeted therapies for RAS-addicted cancers. The company utilizes a proprietary tri-complex technology platform to create RAS(ON) Inhibitors, which target the active, GTP-bound form of RAS. The pipeline includes daraxonrasib (multi-selective), zoldonrasib (G12D-selective), elironrasib (G12C-selective), and RMC-5127 (G12V-selective). The company has no products approved for commercial sale and has incurred significant losses since inception.
Key Financial Metrics
| Metric | 2025 (in millions) | 2024 (in millions) |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(1,131.3) | $(600.1) |
| Research & Development Expenses | $987.3 | $592.2 |
| General & Administrative Expenses | $195.0 | $97.3 |
| Cash, Cash Equivalents, and Marketable Securities | $2,024.2 | $2,287.3 |
| Accumulated Deficit | $(2,869.1) | $(1,737.8) |
| Net Cash Used in Operating Activities | $(897.7) | $(557.4) |
| Net Cash Provided by Financing Activities | $621.5 | $959.4 |
Note: The company reported no revenue in 2025 or 2024. The Sanofi collaboration agreement, which previously generated revenue, was terminated in June 2023.
Material Changes vs. Prior Period
- Increased Operating Expenses: Total operating expenses increased by $492.8 million (71.5%) to $1.18 billion in 2025 compared to $689.5 million in 2024.
- R&D Expenses: Increased by $395.1 million (67%), driven by higher clinical trial and manufacturing costs for daraxonrasib (+$162.1M), zoldonrasib (+$56.1M), and elironrasib (+$18.6M), as well as increased headcount and stock-based compensation.
- G&A Expenses: Doubled to $195.0 million, primarily due to a $34.4 million increase in commercial preparation expenses and increased personnel costs.
- Financing Activities: In June 2025, the company entered into a Royalty Purchase Agreement with Royalty Pharma, receiving $250.0 million in upfront proceeds. Additionally, the company raised $347.9 million net proceeds through its at-the-market (ATM) offering program in 2025.
- Interest Expense: Interest expense of $24.2 million was recorded in 2025, primarily due to non-cash interest associated with the sale of future royalties. There was no interest expense in 2024.
- Warrant Liability: The fair value of warrant liabilities increased by $15.4 million in 2025 due to an increase in the company's share price.
Guidance, Outlook, and Risks
Clinical Outlook and Milestones:
- Daraxonrasib: Received Breakthrough Therapy Designation (June 2025) and Orphan Drug Designation (October 2025) for pancreatic cancer. Also received a Commissioner's National Priority Voucher (CNPV) in October 2025. Phase 3 readout for RASolute 302 (2L PDAC) is expected in the first half of 2026.
- Zoldonrasib: Received Breakthrough Therapy Designation (December 2025) for KRAS G12D-mutated NSCLC. Phase 3 trial RASolute 305 is ongoing in 1L PDAC.
- Elironrasib: Received Breakthrough Therapy Designation (July 2025) for KRAS G12C-mutated NSCLC.
- Future Trials: The company expects to initiate RASolute 309 (daraxonrasib + zoldonrasib in 1L PDAC) in the second half of 2026 and RASolve 308 (zoldonrasib in 1L NSCLC) in the first half of 2026.
Liquidity and Capital Resources:
- As of December 31, 2025, the company held $2.0 billion in cash, cash equivalents, and marketable securities.
- Management believes existing resources will fund planned operations for at least 12 months following the filing date.
- The company has access to up to $1.0 billion in additional synthetic royalty funding (subject to triggers) and a $750.0 million term loan facility (subject to FDA approval milestones).
Key Risks and Contingencies:
- Profitability: The company has never generated revenue from product sales and expects to incur losses for the foreseeable future. It may never achieve profitability.
- Capital Needs: Substantial additional financing will be required to advance clinical trials and prepare for commercialization. Failure to secure funding could force delays or termination of programs.
- Regulatory Approval: Success depends on obtaining marketing approval for product candidates, which is uncertain. Clinical trial results may not be predictive of future outcomes.
- Legal Proceedings: The company is involved in litigation regarding the EQRx merger (Nemeth v. Casdin). An agreement to resolve the matter was filed in January 2026, with an accrued liability of $5.0 million recorded.
- Intellectual Property: The company relies on patents and trade secrets; failure to obtain or maintain protection could allow competitors to commercialize similar products.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $2.0 billion cash balance against the accelerating burn rate (operating cash burn of ~$898M in 2025) and the timeline for potential revenue generation.
- Phase 3 Readouts: Monitor the expected first-half 2026 readout for the RASolute 302 trial (daraxonrasib in 2L PDAC), which is a critical milestone for the Royalty Pharma tranche triggers and potential FDA approval.
- Royalty Agreement Triggers: Review the specific clinical and commercial milestones required to unlock the additional $1.0 billion in potential funding under the Royalty Purchase Agreement.
- Regulatory Designations: Confirm the status of Breakthrough Therapy Designations and the CNPV for daraxonrasib and how these impact the regulatory review timeline.
- Legal Resolution: Track the court approval status of the settlement agreement regarding the EQRx merger litigation to ensure no further financial exposure beyond the accrued $5.0 million.
- Stock-Based Compensation: Assess the impact of increasing stock-based compensation ($118.4M in 2025) on future dilution and expense management.